18 completed, 5 terminated. 23 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Completed 18, Terminated 5 |
| Phase 2 | 1 | Completed 1 |
Follow Tapentadol: new trials by email Literature Review of Tapentadol trials Research Report on Tapentadol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty.Tapentadol vs Oxycodone vs Placebo Tapentadol, Oxycodone, Placebo - Joint Diseases | Phase 3 | Completed | St. Olavs Hospital | 134 | 2015-09-01 | 2021-11-16 |
| A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain Tapentadol prolonged release, Morphine prolonged release - Pain | Phase 2 / Phase 3 | Completed | Grünenthal GmbH | 73 | 2015-04-29 | 2019-09-12 |
| A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain Tapentadol oral solution 4 mg/mL, Tapentadol oral solution 20 mg/mL, Placebo - Acute Pain | Phase 3 | Completed | Grünenthal GmbH | 216 | 2015-02-19 | 2020-01-18 |
| Tapentadol in Chronic Malignant Tumour Related Pain Tapentadol Prolonged Release - Cancer, Chronic Pain | Phase 3 | Terminated | Grünenthal GmbH | 31 | 2011-03-01 | 2019-11-04 |
| A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain Oxycodone CR, R331333 (referred to as JNS024 ER or CG5503) - Pain | Phase 3 | Completed | Janssen Research & Development, LLC | 343 | 2010-08-01 | 2017-07-21 |
| Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability Tapentadol Prolonged Release - Pain, Chronic Pain | Phase 3 | Terminated | Grünenthal GmbH | 136 | 2009-10-30 | 2019-01-09 |
| Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Tapentadol PR, Observation period - Chronic Pain, Low Back Pain | Phase 3 | Completed | Grünenthal GmbH | 208 | 2009-09-30 | 2019-01-15 |
| Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic Tapentadol - Chronic Pain, Osteoarthritis | Phase 3 | Completed | Grünenthal GmbH | 224 | 2009-09-01 | 2019-10-21 |
| Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability. Tapentadol PR - Chronic Pain, Osteoarthritis | Phase 3 | Terminated | Grünenthal GmbH | 82 | 2009-09-01 | 2019-10-18 |
| NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain NUCYNTA, Oxycodone IR - Pain, Back Pain | Phase 3 | Completed | Ortho-McNeil Janssen Scientific Affairs, LLC | 667 | 2009-09-01 | 2012-12-19 |
| A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease oxycodone CR, oxycodone IR, Tapentadol ER (CG5503) - Joint Diseases, Arthritis | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 597 | 2008-10-01 | 2012-02-13 |
| A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy. Tapentadol (CG5503), oxycodone, placebo - Arthralgia, Bunion | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 901 | 2008-02-01 | 2014-05-09 |
| Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain tapentadol (CG5503) Immediate Release IR, tapentadol (CG5503) Extended Release (ER), tapentadol (CG5503) Immediate Release (IR) - Low Back Pain | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 117 | 2007-12-01 | 2015-04-15 |
| A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine Tapentadol Extended Release, Matching Placebo after Tapentadol in the Titration Phase., Morphine Sulphate Controlled Release - Tumor, Pain | Phase 3 | Completed | Grünenthal GmbH | 622 | 2007-07-01 | 2019-11-04 |
| A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine Tapentadol in the Titration Phase, Morphine in the Maintenance Phase, Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase - Pain, Neoplasm | Phase 3 | Terminated | Grünenthal GmbH | 136 | 2007-06-01 | 2019-11-01 |
| An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain Tapentadol (CG5503) Extended Release (ER) - Pain, Osteoarthritis | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1166 | 2007-06-01 | 2014-05-09 |
| A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy Morphine, CG5503 IR, Placebo - Hysterectomy, Postoperative | Phase 3 | Completed | Grünenthal GmbH | 854 | 2007-05-01 | 2019-10-28 |
| A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy CG5503, placebo - Diabetic Neuropathy | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 395 | 2007-04-01 | 2013-07-19 |
| A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain tapentadol (CG5503) ER, oxycodone CR, placebo - Low Back Pain | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 981 | 2007-02-01 | 2012-04-30 |
| Tapentadol (CG5503) oxycodone, placebo, tapentadol (CG5503) - Osteoarthritis, Knee, Pain | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1030 | 2007-01-01 | 2012-04-18 |
Showing 20 of 23. Sign in to see all of them.
Pain (15) · Chronic Pain (8) · Low Back Pain (7) · Osteoarthritis (6) · Arthralgia (4) · Agnosia (3) · Neoplasms (3) · Acute Pain (2) · Back Pain (2) · Joint Diseases (2) · Osteoarthritis, Knee (2) · Abdomen, Acute (1) · Arthritis (1) · Bunion (1) · Cancer Pain (1)
Grünenthal GmbH (10) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (10) · Janssen Research & Development, LLC (1) · Ortho-McNeil Janssen Scientific Affairs, LLC (1) · St. Olavs Hospital (1)
Poland (8) · Spain (8) · France (7) · Germany (7) · United States (7) · United Kingdom (6) · Hungary (5) · Bulgaria (4) · Belgium (3) · Canada (3) · Croatia (3) · Czechia (3) · Italy (3) · Romania (3) · Russia (3)
Barbara Hoggart, Dr. MD (1) · Hans Georg Kress, Dr. (1) · Hans Kress, Prof. MD (1) · Hans-Georg Kress, Prof. Dr. med (1) · Jaime Calvo, Dr. MD (1) · P. Poulain, Dr. (1) · Petter Aadahl, md phd (1) · Tomasz Rechberger, Prof. (1)
PMID 23340531, PMID 24985410, PMID 23709304, PMID 24353047, PMID 24916058, PMID 19445652, PMID 20119464, PMID 20602712, PMID 21162697, PMID 21494892, PMID 22443293, PMID 22792000, PMID 23475406, PMID 23703422, PMID 23937387, PMID 25054392, PMID 26428249, PMID 27062079, PMID 32773594, PMID 35482392
2009 (5), 2015 (1)